$GMED
GLOBUS MEDICAL INC Stock $gmed

$gmed Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000123783120000010 Filed on February 20, 2020

Income Statement

Concept	2019 Q4	2018 Q4	2018 Q3
Revenue	$211.7M	$195.9M	$169.2M
YoY Change	8.03%	11.31%	11.53%
Cost Of Revenue	$48.80M	$46.00M	$37.85M
YoY Change	6.09%	12.47%	2.86%
Gross Profit	$162.9M	$150.0M	$131.4M
YoY Change	8.62%	10.95%	14.3%
Gross Profit Margin	76.96%	76.55%	77.64%
Selling, General & Admin	$92.10M	$83.60M	$75.13M
YoY Change	10.17%	14.52%	18.57%
% of Gross Profit	56.54%	55.74%	57.18%
Research & Development	$15.50M	$13.80M	$15.53M
YoY Change	12.32%	21.05%	42.62%
% of Gross Profit	9.51%	9.2%	11.82%
Depreciation & Amortization	$14.00M	$11.90M	$10.50M
YoY Change	17.65%	43.37%	-3.67%
% of Gross Profit	8.59%	7.93%	7.99%
Operating Expenses	$111.0M	$100.4M	$93.09M
YoY Change	10.56%	15.94%	17.61%
Operating Profit	$51.91M	$49.58M	$38.30M
YoY Change	4.68%	2.07%	7.0%
Interest Expense	$4.400M	$4.200M	$3.800M
YoY Change	4.76%	100.0%	171.43%
% of Operating Profit	8.48%	8.47%	9.92%
Other Income/Expense, Net	$100.0K	$200.0K	$4.296M
YoY Change	-50.0%	0.0%	175.03%
Pretax Income	$54.40M	$47.60M	$42.60M
YoY Change	14.29%	-5.93%	14.03%
Income Tax	$8.900M	$10.90M	$7.389M
% Of Pretax Income	16.36%	22.9%	17.35%
Net Earnings	$45.53M	$36.75M	$35.21M
YoY Change	23.89%	50.77%	37.58%
Net Earnings / Revenue	21.51%	18.76%	20.8%
Basic Earnings Per Share	$0.46	$0.37	$0.36
Diluted Earnings Per Share	$0.44	$0.36	$0.35
COMMON SHARES
Basic Shares Outstanding	99.84M	98.48M shares	98.33M
Diluted Shares Outstanding			101.8M

Balance Sheet

Concept	2019 Q4	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$311.2M	$339.6M	$372.8M
YoY Change	-8.35%	-9.13%	10.38%
Cash & Equivalents	$195.5M	$139.6M	$145.3M
Short-Term Investments	$115.8M	$199.9M	$227.5M
Other Short-Term Assets	$17.20M	$15.40M	$14.00M
YoY Change	11.69%	37.5%	48.94%
Inventory	$196.3M	$131.3M	$124.4M
Prepaid Expenses
Receivables	$154.3M	$137.1M	$118.8M
Other Receivables	$8.100M	$7.300M	$16.50M
Total Short-Term Assets	$687.5M	$630.7M	$646.4M
YoY Change	9.0%	1.67%	14.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$199.8M	$171.9M	$161.8M
YoY Change	16.27%	20.05%	20.53%
Goodwill	$128.8M	$123.7M	$124.0M
YoY Change	4.07%	-0.13%	3.98%
Intangibles	$78.81M	$87.32M	$89.52M
YoY Change	-9.75%	11.01%	2.13%
Long-Term Investments	$409.5M	$263.1M	$168.9M
YoY Change	55.64%	368.98%	186.76%
Other Assets	$21.74M	$10.36M	$6.726M
YoY Change	109.77%	30.41%	-18.77%
Total Long-Term Assets	$844.6M	$670.0M	$592.1M
YoY Change	26.06%	46.23%	25.02%
TOTAL ASSETS
Total Short-Term Assets	$687.5M	$630.7M	$646.4M
Total Long-Term Assets	$844.6M	$670.0M	$592.1M
Total Assets	$1.532B	$1.301B	$1.239B
YoY Change	17.79%	20.6%	19.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.61M	$25.90M	$23.06M
YoY Change	-4.95%	3.42%	39.32%
Accrued Expenses	$63.28M	$59.88M	$47.76M
YoY Change	5.69%	13.85%	2.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$111.4M	$96.12M	$81.72M
YoY Change	15.9%	3.27%	9.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$9.377M	$7.634M	$2.670M
YoY Change	22.83%	208.57%	49.5%
Total Long-Term Liabilities	$9.377M	$7.634M	$2.670M
YoY Change	22.83%	208.57%	49.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$111.4M	$96.12M	$81.72M
Total Long-Term Liabilities	$9.377M	$7.634M	$2.670M
Total Liabilities	$129.6M	$115.2M	$97.39M
YoY Change	12.57%	4.0%	-4.42%
SHAREHOLDERS EQUITY
Retained Earnings	$1.048B	$892.7M	$856.0M
YoY Change	17.39%	21.25%	20.24%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.402B	$1.186B	$1.141B
YoY Change
Total Liabilities & Shareholders Equity	$1.532B	$1.301B	$1.239B
YoY Change	17.79%	20.6%	19.41%

Cashflow Statement

Concept	2019 Q4	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	$45.53M	$36.75M	$35.21M
YoY Change	23.89%	50.77%	37.58%
Depreciation, Depletion And Amortization	$14.00M	$11.90M	$10.50M
YoY Change	17.65%	43.37%	-3.67%
Cash From Operating Activities	$54.30M	$44.20M	$51.80M
YoY Change	22.85%	-1.56%	48.85%
INVESTING ACTIVITIES
Capital Expenditures	-$15.80M	-$17.20M	-$15.30M
YoY Change	-8.14%	28.36%	19.53%
Acquisitions
YoY Change
Other Investing Activities	-$20.20M	-$35.40M	-$13.50M
YoY Change	-42.94%	785.0%	-39.46%
Cash From Investing Activities	-$36.10M	-$52.60M	-$28.90M
YoY Change	-31.37%	202.3%	-17.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.10M	2.900M	2.500M
YoY Change	282.76%	-3000.0%	150.0%
NET CHANGE
Cash From Operating Activities	54.30M	44.20M	51.80M
Cash From Investing Activities	-36.10M	-52.60M	-28.90M
Cash From Financing Activities	11.10M	2.900M	2.500M
Net Change In Cash	29.30M	-5.500M	25.40M
YoY Change	-632.73%	-120.07%	3528.57%
FREE CASH FLOW
Cash From Operating Activities	$54.30M	$44.20M	$51.80M
Capital Expenditures	-$15.80M	-$17.20M	-$15.30M
Free Cash Flow	$70.10M	$61.40M	$67.10M
YoY Change	14.17%	5.32%	40.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001237831
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	gmed	Line Of Credit Termination Period Without Penalty LineOfCreditTerminationPeriodWithoutPenalty	P10D
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-35621
CY2019	dei	Entity Registrant Name EntityRegistrantName	GLOBUS MEDICAL, INC.
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3744954
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	2560 General Armistead Avenue
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Audubon
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19403
CY2019	dei	City Area Code CityAreaCode	610
CY2019	dei	Local Phone Number LocalPhoneNumber	930-1800
CY2019	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $.001 per share
CY2019	dei	Trading Symbol TradingSymbol	GMED
CY2019	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	dei	Entity Public Float EntityPublicFloat	3300000000
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99835463
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	195724000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139747000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	115763000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	199937000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5599000000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4226000000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	154326000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	137067000
CY2019Q4	us-gaap	Inventory Net InventoryNet	196314000
CY2018Q4	us-gaap	Inventory Net InventoryNet	131254000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17243000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15387000
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8098000
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7289000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	687468000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	630681000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	243732000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	216809000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	199841000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	171873000
CY2019Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	409514000
CY2018Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	263117000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	78812000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	87323000
CY2019Q4	us-gaap	Goodwill Goodwill	128775000
CY2018Q4	us-gaap	Goodwill Goodwill	123734000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21741000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10364000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	5926000
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	13578000
CY2019Q4	us-gaap	Assets Assets	1532077000
CY2018Q4	us-gaap	Assets Assets	1300670000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24614000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	25895000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63283000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59878000
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1057000
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	917000
CY2019Q4	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	6727000
CY2018Q4	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	6830000
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5402000
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2598000
CY2019Q4	srt	Payables To Broker Dealers And Clearing Organizations PayablesToBrokerDealersAndClearingOrganizations	10320000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	111403000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	96118000
CY2019Q4	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	2822000
CY2018Q4	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	3288000
CY2019Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6023000
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	8114000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9377000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7634000
CY2019Q4	us-gaap	Liabilities Liabilities	129625000
CY2018Q4	us-gaap	Liabilities Liabilities	115154000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	357320000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	299869000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2898000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7172000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1047931000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	892721000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1402452000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1185516000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1532077000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1300670000
CY2019	us-gaap	Revenues Revenues	785368000
	us-gaap	Revenues Revenues	712969000
CY2017	us-gaap	Revenues Revenues	635977000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	179975000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	159410000
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	150453000
CY2019	us-gaap	Gross Profit GrossProfit	605393000
	us-gaap	Gross Profit GrossProfit	553559000
CY2017	us-gaap	Gross Profit GrossProfit	485524000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60073000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55496000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43679000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	354757000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	311591000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	267817000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13809000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9588000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7909000
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2575000
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1681000
CY2017	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1611000
CY2019	us-gaap	Operating Expenses OperatingExpenses	433404000
	us-gaap	Operating Expenses OperatingExpenses	384234000
CY2017	us-gaap	Operating Expenses OperatingExpenses	323684000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	171989000
	us-gaap	Operating Income Loss OperatingIncomeLoss	169325000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	161840000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	17406000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	13278000
CY2017	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6608000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	75000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	360000
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	909000
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	476000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	5642000
CY2017	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	571000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17957000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19280000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8088000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	189946000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	188605000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	169928000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34736000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32131000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62580000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	155210000
	us-gaap	Net Income Loss NetIncomeLoss	156474000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	107348000
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.60
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.12
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.54
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.10
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99150000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97884000
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96243000
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2848000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3432000
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1644000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101998000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101316000
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97887000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4494000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2451000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2873000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	155210000
	us-gaap	Net Income Loss NetIncomeLoss	156474000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	107348000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3767000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	145000
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-146000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	507000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-410000
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1881000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4274000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-265000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1735000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	159484000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	156209000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	109083000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	832078000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14882000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11735000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	109083000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	967778000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22219000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	39311000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	156209000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1185516000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26416000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31036000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	159484000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1402452000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	155210000
	us-gaap	Net Income Loss NetIncomeLoss	156474000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	107348000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52734000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41630000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42067000
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1089000
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1677000
CY2017	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2671000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	2498000
	us-gaap	Inventory Write Down InventoryWriteDown	10475000
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	11519000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	26085000
	us-gaap	Share Based Compensation ShareBasedCompensation	21899000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	14686000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3026000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	957000
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1718000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	971000
CY2017	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	8292000
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1787000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	985000
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1240000
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4302000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-866000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	3557000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18306000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21789000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24955000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	50018000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	31382000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5277000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12263000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7496000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4774000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	773000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3008000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9843000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7043000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	14728000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2064000
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-673000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-921000
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-3772000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	171975000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	181643000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	159058000
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	346526000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	537942000
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	392895000
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	247008000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	278049000
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	240353000
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	53786000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	106388000
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	122512000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70750000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59697000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51303000
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	5000000
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	23799000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	14825000
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	29944000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-140281000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-193027000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-111277000
CY2019	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	6597000
	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	6739000
CY2017	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	10109000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31036000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	39309000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11735000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24439000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32570000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1626000
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-156000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-256000
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1979000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	55977000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	20930000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	51386000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139747000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118817000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67431000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	195724000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139747000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118817000
CY2019	us-gaap	Interest Paid InterestPaid	79000
	us-gaap	Interest Paid InterestPaid	6000
CY2017	us-gaap	Interest Paid InterestPaid	3000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	34139000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	30552000
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	59111000
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, write-down for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During fourth quarter of 2017, we completed a review of the estimated useful life of our Instruments and Modules and cases. Based on historical useful life information, forecasted product life cycles and demand expectations, the useful life of Instruments and Modules and cases were extended from three to five years. This was accounted for as a change in accounting estimate and was made on a prospective basis effective October 1, 2017. For the three months ended December 31, 2018, depreciation expense was lower by approximately $1.3 million than it would have been had the useful life of these assets not been extended. The effect of this change on basic and diluted earnings per share for the three months ended December 31, 2018 was $0.01 per share. For the year ended December 31, 2018, depreciation expense was lower by approximately $5.7 million than it would have been had the useful life of these assets not been extended, with a diluted earnings per share impact of $0.05 per share</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">(e</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">) Foreign Currency Translation</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The functional currency of our foreign subsidiaries is generally their local currency. Assets and liabilities of the foreign subsidiaries are translated at the period end currency exchange rate and revenues and expenses are translated at an average currency exchange rate for the </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">period. The resulting foreign currency translation gains and losses are included as a component of accumulated other comprehensive income. Gains and losses arising from intercompany foreign transactions are included in other income, net on the consolidated statement of income</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195474000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139647000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118817000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66954000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	250000
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	100000
CY2016Q4	us-gaap	Restricted Cash RestrictedCash	477000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	195724000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139747000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118817000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67431000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">(g) Concentrations of Credit Risk</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments, which potentially subject us to concentrations of credit risk, are primarily marketable securities and accounts receivable. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of entities comprising our customer base. We perform ongoing credit evaluations of our customers and generally do not require collateral.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There was no customer that accounted for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% or more of sales for the years ended December 31, 2019, 2018, and 2017, respectively.</span></p>
CY2019	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.10
CY2019	gmed	Payable To Broker PayableToBroker	10300000
CY2019	gmed	Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory	2500000
CY2018	gmed	Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory	10500000
CY2017	gmed	Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory	11500000
CY2019	gmed	Excess And Obsolete Related Provisions ExcessAndObsoleteRelatedProvisions	11200000
CY2018	gmed	Excess And Obsolete Related Provisions ExcessAndObsoleteRelatedProvisions	17600000
CY2017	gmed	Excess And Obsolete Related Provisions ExcessAndObsoleteRelatedProvisions	20700000
CY2019	gmed	Inventory Sales And Disposals Related Provisions InventorySalesAndDisposalsRelatedProvisions	8700000
CY2018	gmed	Inventory Sales And Disposals Related Provisions InventorySalesAndDisposalsRelatedProvisions	7100000
CY2017	gmed	Inventory Sales And Disposals Related Provisions InventorySalesAndDisposalsRelatedProvisions	9200000
CY2019	gmed	Property Purchases In Accounts Payable And Accrued Expenses PropertyPurchasesInAccountsPayableAndAccruedExpenses	4200000
CY2018	gmed	Property Purchases In Accounts Payable And Accrued Expenses PropertyPurchasesInAccountsPayableAndAccruedExpenses	10100000
CY2017	gmed	Property Purchases In Accounts Payable And Accrued Expenses PropertyPurchasesInAccountsPayableAndAccruedExpenses	6500000
CY2017	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	500000
CY2019Q4	us-gaap	Revenues Revenues	211667000
CY2018Q4	us-gaap	Revenues Revenues	195938000
CY2017Q4	us-gaap	Revenues Revenues	176034000
CY2019	us-gaap	Revenues Revenues	785368000
CY2018	us-gaap	Revenues Revenues	712969000
CY2017	us-gaap	Revenues Revenues	635977000
CY2018Q2	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	5000000.0
CY2018Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	4600000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	1100000
CY2018	us-gaap	Advertising Expense AdvertisingExpense	1900000
CY2017	us-gaap	Advertising Expense AdvertisingExpense	1500000
CY2020	gmed	Medical Device Excise Tax Percentage MedicalDeviceExciseTaxPercentage	2.3
CY2019	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	28100000
CY2019	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	23800000
CY2019Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability	4300000
CY2019Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	15300000
CY2019Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	4200000
CY2019Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	3900000
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	4800000
CY2019Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability	5000000.0
CY2019	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	29300000
CY2019Q4	gmed	Intangible Assets Gross IntangibleAssetsGross	117005000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	38193000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	78812000
CY2018Q4	gmed	Intangible Assets Gross IntangibleAssetsGross	111537000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24214000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	87323000
CY2018Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	15200000
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10000000.0
CY2017Q4	us-gaap	Goodwill Goodwill	123890000
CY2018	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-156000
CY2018Q4	us-gaap	Goodwill Goodwill	123734000
CY2019	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	4817000
CY2019	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	224000
CY2019Q4	us-gaap	Goodwill Goodwill	128775000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	13859000000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	13623000000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	13070000000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11012000000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8046000000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	19202000000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	78812000000
CY2019Q4	gmed	Cash Equivalents Fair Value Disclosure CashEquivalentsFairValueDisclosure	18218000
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9549000
CY2018Q4	gmed	Cash Equivalents Fair Value Disclosure CashEquivalentsFairValueDisclosure	48040000
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10118000
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	20740000
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9549000
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10118000
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	15919000
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Basis For Amount BusinessCombinationContingentConsiderationArrangementsBasisForAmount	4,299
	us-gaap	Business Combination Contingent Consideration Arrangements Basis For Amount BusinessCombinationContingentConsiderationArrangementsBasisForAmount	—
CY2019	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	-58000
	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	-48000
CY2019	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-6597000
	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-6738000
CY2019	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	1787000
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	985000
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9549000
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10118000
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	33025000
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	15940000
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	13179000
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	147349000
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	97335000
CY2019Q4	us-gaap	Inventory Net InventoryNet	196314000
CY2018Q4	us-gaap	Inventory Net InventoryNet	131254000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	443573000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	388682000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	243732000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	216809000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	199841000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	171873000
CY2019	us-gaap	Depreciation Depreciation	38924000
CY2018	us-gaap	Depreciation Depreciation	32042000
CY2017	us-gaap	Depreciation Depreciation	34158000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	37178000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32465000
CY2019Q4	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	1538000
CY2018Q4	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	6684000
CY2019Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4996000
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3593000
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2370000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2500000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17201000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14636000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63283000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59878000
CY2011Q2	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	50000000.0
CY2018Q2	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	50000000.0
CY2019Q4	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	125000000.0
CY2019Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	150000000.0
CY2019	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.0075
CY2019Q4	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	125000000.0
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	785000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99825080
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99825080
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98573354
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98573354
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6907000
CY2018	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-250000
CY2018	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-15000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-265000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7172000
CY2019	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	5439000
CY2019	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-1165000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4274000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2898000
CY2019Q4	gmed	Share Based Compensation Number Of Stock Plans ShareBasedCompensationNumberOfStockPlans	3
CY2019Q4	gmed	Share Based Compensation Arrangement By Share Based Payment Award Base Number Of Shares Issuable ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfSharesIssuable	3076923
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.90
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.12
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0135
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0257
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.290
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9668000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.45
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2920000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	46.55
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1251000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.86
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	687000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.08
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10650000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.80
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	245781000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5063000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.44
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	159155000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5587000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	43.37
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	86625000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	31315000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	59345000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12217000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26085000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21899000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14686000
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	331000
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	320000
CY2017	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	196000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	26416000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	22219000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	14882000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	179194000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	180701000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	155051000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	10752000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	7904000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	14877000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	189946000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	188605000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	169928000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	23093000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	23774000
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	46728000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4532000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4662000
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5009000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2819000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2724000
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2638000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30444000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	31160000
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	54375000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	6542000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	4155000
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	10553000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-68000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-587000
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1123000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2182000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2597000
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1225000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4292000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	971000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8205000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34736000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32131000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62580000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.004
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.017
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	-0.006
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	-0.007
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	-0.023
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.026
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.016
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.038
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.025
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.052
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.014
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.006
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.065
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.183
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.170
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.368
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	26381000
CY2018Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	25398000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	8620000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	10377000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14020000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10959000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	3857000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	3852000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	52878000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50586000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2846000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2683000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	50032000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	47903000
CY2019Q4	gmed	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	50129000
CY2018Q4	gmed	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	42439000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	50129000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	42439000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	-97000
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	5464000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2800000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2700000
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	21400000
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24000000.0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4777000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2601000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1862000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2176000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	739000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2378000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2399000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4777000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2601000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2400000
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2878000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4084000
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2076000
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2481000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1339000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1142000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2481000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	3174000
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.00034
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	1451000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	553000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	315000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	226000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	110000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2660000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	179000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2481000
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2500000
CY2019Q4	gmed	Prepaidroyalty Prepaidroyalty	9000000.0
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	6000
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5363000000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4682000000
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3597000000
CY2019	us-gaap	Revenues Revenues	785368000
	us-gaap	Revenues Revenues	712969000
CY2017	us-gaap	Revenues Revenues	635977000
CY2019Q1	us-gaap	Revenues Revenues	182947000
CY2019Q2	us-gaap	Revenues Revenues	194539000
CY2019Q3	us-gaap	Revenues Revenues	196215000
CY2019Q4	us-gaap	Revenues Revenues	211667000
CY2019Q1	us-gaap	Gross Profit GrossProfit	141109000
CY2019Q2	us-gaap	Gross Profit GrossProfit	150549000
CY2019Q3	us-gaap	Gross Profit GrossProfit	150828000
CY2019Q4	us-gaap	Gross Profit GrossProfit	162907000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	33210000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	38163000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	38307000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	45530000
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
CY2018Q1	us-gaap	Revenues Revenues	174411000
CY2018Q2	us-gaap	Revenues Revenues	173384000
CY2018Q3	us-gaap	Revenues Revenues	169236000
CY2018Q4	us-gaap	Revenues Revenues	195938000
CY2018Q1	us-gaap	Gross Profit GrossProfit	136441000
CY2018Q2	us-gaap	Gross Profit GrossProfit	135747000
CY2018Q3	us-gaap	Gross Profit GrossProfit	131387000
CY2018Q4	us-gaap	Gross Profit GrossProfit	149984000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	39538000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	44977000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	35208000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	36751000
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.37
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.35
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36

Files In Submission

Name	View Source	Status
0001237831-20-000010-index-headers.html	Edgar Link	pending
0001237831-20-000010-index.html	Edgar Link	pending
0001237831-20-000010.txt	Edgar Link	pending
0001237831-20-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gmed-20191231.xsd	Edgar Link	pending
gmed-20191231x10k.htm	Edgar Link	pending
gmed-20191231x10kg001.jpg	Edgar Link	pending
gmed-20191231x10k_htm.xml	Edgar Link	completed
gmed-20191231xex21_1.htm	Edgar Link	pending
gmed-20191231xex23_1.htm	Edgar Link	pending
gmed-20191231xex31_1.htm	Edgar Link	pending
gmed-20191231xex31_2.htm	Edgar Link	pending
gmed-20191231xex32.htm	Edgar Link	pending
gmed-20191231xex4_2.htm	Edgar Link	pending
gmed-20191231_cal.xml	Edgar Link	unprocessable
gmed-20191231_def.xml	Edgar Link	unprocessable
gmed-20191231_lab.xml	Edgar Link	unprocessable
gmed-20191231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GMED
GLOBUS MEDICAL INC Stock $gmed

2019 Q4 Form 10-K Financial Statement

#000123783120000010 Filed on February 20, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED GLOBUS MEDICAL INC Stock $gmed

2019 Q4 Form 10-K Financial Statement

#000123783120000010 Filed on February 20, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED
GLOBUS MEDICAL INC Stock $gmed